Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30539127 | 1.00 | MAPT (0.49) | MAPTMEN1KMT2AKIF11LMNA | |
| SCHEMBL24168437 | 0.87 | MAPT (0.54) | MAPTMEN1KMT2AKIF11LMNA | |
| SCHEMBL8144288 | 0.86 | MAPT (0.51) | MAPTMEN1KMT2AKIF11LMNA | |
| SCHEMBL31009356 | 0.85 | MAPT (0.49) | MAPTMEN1KMT2AKIF11LMNA | |
| SCHEMBL8152290 | 0.83 | MAPT (0.48) | MAPTMEN1KMT2AKIF11LMNA | |
| SCHEMBL2576415 | 0.83 | ALDH1A1 (0.61) | MAPTMEN1KMT2AKIF11LMNA | |
| SCHEMBL17472467 | 0.83 | MAPT (0.49) | MAPTMEN1KMT2AKIF11LMNA | |
| SCHEMBL15794676 | 0.80 | ALDH1A1 (0.62) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL3543571 | 0.79 | ALDH1A1 (0.46) | MAPTMEN1KMT2AKIF11LMNA | |
| SCHEMBL22687001 | 0.79 | HSPB1 (0.61) | MAPTMEN1KMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | BRIDGENE BIOSCIENCES, INC. | 2023-09-14 | — | — | US | disclosed |
| CN-116490201-A | Inhibitors of YAP/TAZ-TEAD tumor proteins, their synthesis and use | 布里奇恩生物科学公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-1866287-B1 | SUBSTITUTED PYRAZOLYL OXYPHENYL DERIVATIVES USED AS HERBICIDES | BAYER IP GMBH (DE) | 2016-09-21 | — | — | EP | disclosed |
| EP-1866287-A2 | SUBSTITUTED PYRAZOLYL OXYPHENYL DERIVATIVES USED AS HERBICIDES | Bayer CropScience AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103003-A2 | SUBSTITUTED PYRAZOLYL OXYPHENYL DERIVATIVES USED AS HERBICIDES | BAYER CROPSCIENCE AG (DE) | 2006-10-05 | — | — | WO | disclosed |
| US-20060223709-A1 | Substituted pyrazolyloxyphenyl derivatives as herbicides | BAYER CROPSCIENCE GMBH (DE) | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286904-A1 | INHIBITORS OF YAP/TAZ-TEAD ONCOPROTEINS, SYNTHESIS AND USE THEREOF | TEAD1, TEAD2, TEAD3 | MAPT 433/4885MEN1 624/4885KMT2A 825/4885 |
| US-20060223709-A1 | Substituted pyrazolyloxyphenyl derivatives as herbicides | DDT, CBR3, CYP1A1 | MAPT 3666/4885MEN1 4204/4885KMT2A 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.